A study to investigate the expression of nuclear Met and its clinical significance in HCC

Abstract

In the world, hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality and the fifth most common cancer overall. As long as the prognosis for HCC remains poor, better therapeutic options will be available if the underlying mechanisms contributing to hepatocarcino-genesis can be elucidated. Human tumours are drawn to the Met/HGF signalling pathway because it has been linked in several types of cancer, including HCC. Current clinical trials are testing treatment techniques that target the Met surface receptor. Because receptor tyrosine kinase signalling has long been believed to occur at the membrane surface, the discovery of Met inside the nucleus raises the possibility of a new "signalling shortcut."

Using three key objectives as a focus, we aimed to provide a thorough knowledge of nuclear Met's role in HCC tumorigenesis and development, as well as the underlying signalling network mediated by nuclear Met in this study.